Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in PD-L1 Positive Advanced NSCLC
NCT02007070Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2014
- Primary completion
- Jul 2015
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Merck & Co. Primary endpoints: Overall Response Rate at 2 years, Adverse Events at 27 months and 1 more. Started Feb 2014; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02007070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02007070.